Previous studies have shown that D3 receptor antagonists, which have structural homology to tyrosine kinase inhibitors (TKIs) like nilotinib, which are known ABCG2 modulators, have efficacy in cancer cells overexpressing ABCG2 transporters [19]. Here, ABCG2 is linked to cancer.